-
Lymphocyte Recirculation
published: 04 Apr 2017
-
Immunology | T- Cell Development
Official Ninja Nerd Website: https://ninjanerd.org
Ninja Nerds!
Join Professor Zach Murphy for our lecture about the thymus gland and T-cell development. We go into detail on positive and negative selection, and the movement to secondary lymphatic organs. We hope you enjoy this lecture and be sure to support us below!
References:
● Steve Ford. 2020. [Digital photo] The lymphatic system 2: structure and function of the lymphoid organs https://www.nursingtimes.net/clinical-archive/immunology/the-lymphatic-system-2-structure-and-function-of-the-lymphoid-organs-26-10-2020/
● Vector Shock Lymph node structure medical educational vector image. [Digital photo ] https://www.vectorstock.com/royalty-free-vector/lymph-node-structure-medical-educational-vector-8377264
● Indiana University. Histology...
published: 08 Apr 2017
-
Medical vocabulary: What does Receptors, CXCR5 mean
What does Receptors, CXCR5 mean in English?
published: 20 Jan 2016
-
Lecture 5b: B Cell Signaling + Activation
UCSD Extension School: Applied Immunology (BIOL-40371)
Spring Quarter 2021
This lecture summarizes signal transduction pathways engaged downstream of B cell receptor (BCR) signaling and provides a comparison to analogous pathways engaged downstream of the T cell receptor (TCR). It also covers the 2 main categories of antigens that can activate B cells, and the effects that these have on either IgM antibody responses that provide immediate protection or germinal center responses that provide higher quality antibodies through the processes of affinity maturation and class switching.
All figures are either from Janeway's Immunobiology (9th ed.) where noted, or my own original figures.
published: 24 Mar 2021
-
CXCR5+ T helper cells mediate protective immunity against tuberculosis
Shabaana Khader of the University of Pittsburgh discusses the identification of immune parameters that distinguish active and latent TB infections. Highlights:
• One-third of the world's population is infected with Mycobacterium tuberculosis; however, only 5%–10% will develop active infections.
• Individuals with latent infections have a 10% lifetime risk of developing active tuberculosis. This risk increases to 10% per year in the presence of HIV infection. It is therefore important to identify immunologic features that distinguish active TB from latent.
• Granulomas are immune cell aggregates that are a hallmark of TB infection. They play a protective role in latent TB but can promote infection during active TB.
• Using human, nonhuman primate, and mouse models of TB infection, Khader a...
published: 07 Jan 2013
-
Resistance HIV & AIDS - CCR5 & CXCR4, Eng. [CCR5delta32 - CCR5 tropic, Dual tropic, CXCR4 tropic]
Resistance HIV & AIDS - CCR5 & CXCR4, Eng. [CCR5delta32 - CCR5 tropic, Dual tropic, CXCR4 tropic]
https://en.wikipedia.org/wiki/CCR5
https://en.wikipedia.org/wiki/CXCR4
published: 08 Mar 2019
-
Gene Music using Protein Sequence of CXCR5 "CHEMOKINE (C-X-C MOTIF) RECEPTOR 5"
Shop CXCR5
➜ https://www.redbubble.com/people/genemusic/works/46809186-cxcr5?asc=u
Own unique copy of CXCR5 NFT at OpenSea:
➜ https://opensea.io/assets/matic/0x2953399124f0cbb46d2cbacd8a89cf0599974963/19760280059658156473802018415659714340384995726990286024916400305166738259969/
Subscribe ➜ https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Gene Music Studio - A channel to taste (visually & musically) gene information (particularly protein sequences)
Gene Music using Protein Sequence of CXCR5 'CHEMOKINE (C-X-C MOTIF) RECEPTOR 5'
published: 21 Apr 2016
-
Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells
This Harvard Medical School Continuing Education video examines these key questions: what are CAR T cells, in what diseases are they utilized, and what are the common toxicities of CAR T cells?
Dr. Connor Johnson, MD, an oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor cell therapy (CAR T) with a particular focus on lymphoma. The logistics of CAR T-cell therapy are described and toxicities are identified, including cytokine release syndrome (CRS), ICANS, and cytopenias.
00:00 | Introduction
00:37 | Overview of CAR T cells and immunology principles
02:16 | CAR T cells therapies and targets
02:48 | Logistics of CAR T-cell therapy
03:43 | Toxicities related to CAR T-cell therapy
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of...
published: 02 Sep 2022
-
B cell Activaiton And Differentiation
published: 14 Apr 2017
-
Migration of Naive T-cells to Secondary Lymphoid Organs/Tissues
published: 29 Mar 2022
23:50
Immunology | T- Cell Development
Official Ninja Nerd Website: https://ninjanerd.org
Ninja Nerds!
Join Professor Zach Murphy for our lecture about the thymus gland and T-cell development. We go...
Official Ninja Nerd Website: https://ninjanerd.org
Ninja Nerds!
Join Professor Zach Murphy for our lecture about the thymus gland and T-cell development. We go into detail on positive and negative selection, and the movement to secondary lymphatic organs. We hope you enjoy this lecture and be sure to support us below!
References:
● Steve Ford. 2020. [Digital photo] The lymphatic system 2: structure and function of the lymphoid organs https://www.nursingtimes.net/clinical-archive/immunology/the-lymphatic-system-2-structure-and-function-of-the-lymphoid-organs-26-10-2020/
● Vector Shock Lymph node structure medical educational vector image. [Digital photo ] https://www.vectorstock.com/royalty-free-vector/lymph-node-structure-medical-educational-vector-8377264
● Indiana University. Histology of Spleen [Digital image] https://vmicro.iusm.iu.edu/hs_vm/docs/lab7_6.htm
● Teach Me Anatomy. Tonsils [Digital Image] https://teachmeanatomy.info/neck/misc/tonsils-and-adenoids/
● Varsity Tutors. MCAT Biology [Quiz] https://www.varsitytutors.com/mcat_biology-help/lymphoid-organs
● Le T, Bhushan V, Sochat M, Chavda Y, Zureick A. First Aid for the USMLE Step 1 2018. New York, NY: McGraw-Hill Medical; 2017
● Marieb EN, Hoehn K. Anatomy & Physiology. Hoboken, NJ: Pearson; 2020.
● Boron WF, Boulpaep EL. Medical Physiology.; 2017.
● Urry LA, Cain ML, Wasserman SA, Minorsky PV, Orr RB, Campbell NA. Campbell Biology. New York, NY: Pearson; 2020.
● Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. New York etc.: McGraw-Hill Education; 2018.
● lberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P . Molecular Biology of the Cell. New York, NY: Garland Science; 2002
● Murphy K, Weaver C. Janeway's Immunobiology. Garland Science; 2016
● Doan T, Melvold R, Viselli S, Waltenbaugh C. Immunology. Lippincott Williams & Wilkins; 2012
● Levinson W. Review of Medical Microbiology and Immunology. Lange; 2012
Join this channel to get access to perks:
https://www.youtube.com/channel/UC6QYFutt9cluQ3uSM963_KQ/join
APPAREL |
We are switching merchandise suppliers.
DONATE
PATREON | https://www.patreon.com/NinjaNerdScience
PAYPAL | https://www.paypal.com/paypalme/ninjanerdscience
SOCIAL MEDIA
FACEBOOK | https://www.facebook.com/NinjaNerdlectures
INSTAGRAM | https://www.instagram.com/ninjanerdlectures
TWITTER | https://twitter.com/ninjanerdsci
@NinjaNerdSci
DISCORD | https://discord.gg/3srTG4dngW
#ninjanerd #TcellDevelopment #Immunology
https://wn.com/Immunology_|_T_Cell_Development
Official Ninja Nerd Website: https://ninjanerd.org
Ninja Nerds!
Join Professor Zach Murphy for our lecture about the thymus gland and T-cell development. We go into detail on positive and negative selection, and the movement to secondary lymphatic organs. We hope you enjoy this lecture and be sure to support us below!
References:
● Steve Ford. 2020. [Digital photo] The lymphatic system 2: structure and function of the lymphoid organs https://www.nursingtimes.net/clinical-archive/immunology/the-lymphatic-system-2-structure-and-function-of-the-lymphoid-organs-26-10-2020/
● Vector Shock Lymph node structure medical educational vector image. [Digital photo ] https://www.vectorstock.com/royalty-free-vector/lymph-node-structure-medical-educational-vector-8377264
● Indiana University. Histology of Spleen [Digital image] https://vmicro.iusm.iu.edu/hs_vm/docs/lab7_6.htm
● Teach Me Anatomy. Tonsils [Digital Image] https://teachmeanatomy.info/neck/misc/tonsils-and-adenoids/
● Varsity Tutors. MCAT Biology [Quiz] https://www.varsitytutors.com/mcat_biology-help/lymphoid-organs
● Le T, Bhushan V, Sochat M, Chavda Y, Zureick A. First Aid for the USMLE Step 1 2018. New York, NY: McGraw-Hill Medical; 2017
● Marieb EN, Hoehn K. Anatomy & Physiology. Hoboken, NJ: Pearson; 2020.
● Boron WF, Boulpaep EL. Medical Physiology.; 2017.
● Urry LA, Cain ML, Wasserman SA, Minorsky PV, Orr RB, Campbell NA. Campbell Biology. New York, NY: Pearson; 2020.
● Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. New York etc.: McGraw-Hill Education; 2018.
● lberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P . Molecular Biology of the Cell. New York, NY: Garland Science; 2002
● Murphy K, Weaver C. Janeway's Immunobiology. Garland Science; 2016
● Doan T, Melvold R, Viselli S, Waltenbaugh C. Immunology. Lippincott Williams & Wilkins; 2012
● Levinson W. Review of Medical Microbiology and Immunology. Lange; 2012
Join this channel to get access to perks:
https://www.youtube.com/channel/UC6QYFutt9cluQ3uSM963_KQ/join
APPAREL |
We are switching merchandise suppliers.
DONATE
PATREON | https://www.patreon.com/NinjaNerdScience
PAYPAL | https://www.paypal.com/paypalme/ninjanerdscience
SOCIAL MEDIA
FACEBOOK | https://www.facebook.com/NinjaNerdlectures
INSTAGRAM | https://www.instagram.com/ninjanerdlectures
TWITTER | https://twitter.com/ninjanerdsci
@NinjaNerdSci
DISCORD | https://discord.gg/3srTG4dngW
#ninjanerd #TcellDevelopment #Immunology
- published: 08 Apr 2017
- views: 886947
32:09
Lecture 5b: B Cell Signaling + Activation
UCSD Extension School: Applied Immunology (BIOL-40371)
Spring Quarter 2021
This lecture summarizes signal transduction pathways engaged downstream of B cell rec...
UCSD Extension School: Applied Immunology (BIOL-40371)
Spring Quarter 2021
This lecture summarizes signal transduction pathways engaged downstream of B cell receptor (BCR) signaling and provides a comparison to analogous pathways engaged downstream of the T cell receptor (TCR). It also covers the 2 main categories of antigens that can activate B cells, and the effects that these have on either IgM antibody responses that provide immediate protection or germinal center responses that provide higher quality antibodies through the processes of affinity maturation and class switching.
All figures are either from Janeway's Immunobiology (9th ed.) where noted, or my own original figures.
https://wn.com/Lecture_5B_B_Cell_Signaling_Activation
UCSD Extension School: Applied Immunology (BIOL-40371)
Spring Quarter 2021
This lecture summarizes signal transduction pathways engaged downstream of B cell receptor (BCR) signaling and provides a comparison to analogous pathways engaged downstream of the T cell receptor (TCR). It also covers the 2 main categories of antigens that can activate B cells, and the effects that these have on either IgM antibody responses that provide immediate protection or germinal center responses that provide higher quality antibodies through the processes of affinity maturation and class switching.
All figures are either from Janeway's Immunobiology (9th ed.) where noted, or my own original figures.
- published: 24 Mar 2021
- views: 4259
4:32
CXCR5+ T helper cells mediate protective immunity against tuberculosis
Shabaana Khader of the University of Pittsburgh discusses the identification of immune parameters that distinguish active and latent TB infections. Highlights:
...
Shabaana Khader of the University of Pittsburgh discusses the identification of immune parameters that distinguish active and latent TB infections. Highlights:
• One-third of the world's population is infected with Mycobacterium tuberculosis; however, only 5%–10% will develop active infections.
• Individuals with latent infections have a 10% lifetime risk of developing active tuberculosis. This risk increases to 10% per year in the presence of HIV infection. It is therefore important to identify immunologic features that distinguish active TB from latent.
• Granulomas are immune cell aggregates that are a hallmark of TB infection. They play a protective role in latent TB but can promote infection during active TB.
• Using human, nonhuman primate, and mouse models of TB infection, Khader and colleagues identified a subset of T helper cells (CXCR5+) that are associated with protective granulomas in latent TB.
• These results identify a previously unexpected role for CXCR5 in the control of TB infection and could be used to improve TB vaccine strategies.
Article: http://www.jci.org/articles/view/65728
https://wn.com/Cxcr5_T_Helper_Cells_Mediate_Protective_Immunity_Against_Tuberculosis
Shabaana Khader of the University of Pittsburgh discusses the identification of immune parameters that distinguish active and latent TB infections. Highlights:
• One-third of the world's population is infected with Mycobacterium tuberculosis; however, only 5%–10% will develop active infections.
• Individuals with latent infections have a 10% lifetime risk of developing active tuberculosis. This risk increases to 10% per year in the presence of HIV infection. It is therefore important to identify immunologic features that distinguish active TB from latent.
• Granulomas are immune cell aggregates that are a hallmark of TB infection. They play a protective role in latent TB but can promote infection during active TB.
• Using human, nonhuman primate, and mouse models of TB infection, Khader and colleagues identified a subset of T helper cells (CXCR5+) that are associated with protective granulomas in latent TB.
• These results identify a previously unexpected role for CXCR5 in the control of TB infection and could be used to improve TB vaccine strategies.
Article: http://www.jci.org/articles/view/65728
- published: 07 Jan 2013
- views: 1870
6:38
Resistance HIV & AIDS - CCR5 & CXCR4, Eng. [CCR5delta32 - CCR5 tropic, Dual tropic, CXCR4 tropic]
Resistance HIV & AIDS - CCR5 & CXCR4, Eng. [CCR5delta32 - CCR5 tropic, Dual tropic, CXCR4 tropic]
https://en.wikipedia.org/wiki/CCR5
https://en.wikipedia.org/w...
Resistance HIV & AIDS - CCR5 & CXCR4, Eng. [CCR5delta32 - CCR5 tropic, Dual tropic, CXCR4 tropic]
https://en.wikipedia.org/wiki/CCR5
https://en.wikipedia.org/wiki/CXCR4
https://wn.com/Resistance_Hiv_Aids_Ccr5_Cxcr4,_Eng._Ccr5Delta32_Ccr5_Tropic,_Dual_Tropic,_Cxcr4_Tropic
Resistance HIV & AIDS - CCR5 & CXCR4, Eng. [CCR5delta32 - CCR5 tropic, Dual tropic, CXCR4 tropic]
https://en.wikipedia.org/wiki/CCR5
https://en.wikipedia.org/wiki/CXCR4
- published: 08 Mar 2019
- views: 5594
1:36
Gene Music using Protein Sequence of CXCR5 "CHEMOKINE (C-X-C MOTIF) RECEPTOR 5"
Shop CXCR5
➜ https://www.redbubble.com/people/genemusic/works/46809186-cxcr5?asc=u
Own unique copy of CXCR5 NFT at OpenSea:
➜ https://opensea.io/assets/matic/0...
Shop CXCR5
➜ https://www.redbubble.com/people/genemusic/works/46809186-cxcr5?asc=u
Own unique copy of CXCR5 NFT at OpenSea:
➜ https://opensea.io/assets/matic/0x2953399124f0cbb46d2cbacd8a89cf0599974963/19760280059658156473802018415659714340384995726990286024916400305166738259969/
Subscribe ➜ https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Gene Music Studio - A channel to taste (visually & musically) gene information (particularly protein sequences)
Gene Music using Protein Sequence of CXCR5 'CHEMOKINE (C-X-C MOTIF) RECEPTOR 5'
https://wn.com/Gene_Music_Using_Protein_Sequence_Of_Cxcr5_Chemokine_(C_X_C_Motif)_Receptor_5
Shop CXCR5
➜ https://www.redbubble.com/people/genemusic/works/46809186-cxcr5?asc=u
Own unique copy of CXCR5 NFT at OpenSea:
➜ https://opensea.io/assets/matic/0x2953399124f0cbb46d2cbacd8a89cf0599974963/19760280059658156473802018415659714340384995726990286024916400305166738259969/
Subscribe ➜ https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Gene Music Studio - A channel to taste (visually & musically) gene information (particularly protein sequences)
Gene Music using Protein Sequence of CXCR5 'CHEMOKINE (C-X-C MOTIF) RECEPTOR 5'
- published: 21 Apr 2016
- views: 127
6:13
Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells
This Harvard Medical School Continuing Education video examines these key questions: what are CAR T cells, in what diseases are they utilized, and what are the ...
This Harvard Medical School Continuing Education video examines these key questions: what are CAR T cells, in what diseases are they utilized, and what are the common toxicities of CAR T cells?
Dr. Connor Johnson, MD, an oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor cell therapy (CAR T) with a particular focus on lymphoma. The logistics of CAR T-cell therapy are described and toxicities are identified, including cytokine release syndrome (CRS), ICANS, and cytopenias.
00:00 | Introduction
00:37 | Overview of CAR T cells and immunology principles
02:16 | CAR T cells therapies and targets
02:48 | Logistics of CAR T-cell therapy
03:43 | Toxicities related to CAR T-cell therapy
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Arielle J Medford, MD, Senior Medical Oncology Fellow, Dana-Farber Cancer Institute and Anna Handorf, MD, Research Fellow in Pediatrics, Massachusetts General Hospital.
References:
Gaudino SJ and Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front Immunol. 2019 Mar 6;10:360.
Kawalekar OU, O'Connor RS, Fraietta JA, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016;44(2):380-390. doi:10.1016/j.immuni.2016.01.021
Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo [published correction appears in Mol Ther. 2015 Jul;23(7):1278]. Mol Ther. 2009;17(8):1453-1464. doi:10.1038/mt.2009.83
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0
Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347
Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850
Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8
Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866
Hartmann J et al. Clinical development of CAR T-cells—challenges and opportunities in translating innovative treatment. EMBO Mol Med. 2017 Sep;9(9):1183-1197.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. Published 2018 Jun 15. doi:10.1186/s40425-018-0343-9
Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758
Notice: At this time, the content in this video is not accredited.
https://wn.com/Lymphoma_Overview_Of_Chimeric_Antigen_Receptor_(Car)_T_Cells
This Harvard Medical School Continuing Education video examines these key questions: what are CAR T cells, in what diseases are they utilized, and what are the common toxicities of CAR T cells?
Dr. Connor Johnson, MD, an oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor cell therapy (CAR T) with a particular focus on lymphoma. The logistics of CAR T-cell therapy are described and toxicities are identified, including cytokine release syndrome (CRS), ICANS, and cytopenias.
00:00 | Introduction
00:37 | Overview of CAR T cells and immunology principles
02:16 | CAR T cells therapies and targets
02:48 | Logistics of CAR T-cell therapy
03:43 | Toxicities related to CAR T-cell therapy
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Arielle J Medford, MD, Senior Medical Oncology Fellow, Dana-Farber Cancer Institute and Anna Handorf, MD, Research Fellow in Pediatrics, Massachusetts General Hospital.
References:
Gaudino SJ and Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front Immunol. 2019 Mar 6;10:360.
Kawalekar OU, O'Connor RS, Fraietta JA, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016;44(2):380-390. doi:10.1016/j.immuni.2016.01.021
Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo [published correction appears in Mol Ther. 2015 Jul;23(7):1278]. Mol Ther. 2009;17(8):1453-1464. doi:10.1038/mt.2009.83
Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0
Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347
Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850
Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8
Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866
Hartmann J et al. Clinical development of CAR T-cells—challenges and opportunities in translating innovative treatment. EMBO Mol Med. 2017 Sep;9(9):1183-1197.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. Published 2018 Jun 15. doi:10.1186/s40425-018-0343-9
Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758
Notice: At this time, the content in this video is not accredited.
- published: 02 Sep 2022
- views: 27713